hematology-2018-scientifictracks

Page 12

Notes:

Journal of Hematology and Blood Disorder | Volume 2

allied

academies

August 23-24, 2018 | London, UK

Hematology and Oncology

International Conference on

ith modern medical developments various malignant

disorders such as leukemia or solid organ cancers, have

been transformed from acute life-threatening into chronic

diseases. This transition continues with the growing number

of novel agents that become available to treat diseases from

chronic leukemias to breast cancer, or carcinoma of the lung.

Patients are certainly aware of that, and a frequent question is:

“Well, doctor, I know I have already received two treatments

and have not responded. What are we going to do if this next

treatment is not going to work?” In fact, it happens that you

treat patients and basically have conveyed the message that we

are at the end of the road, the patient considering transition to

palliative or hospice care, when a new study is published with

yet another agent, opening the door again, basically returning

the patient from hospice to active therapy. These situations

come with considerable psychological stress. In addition,

however, the cost of this type of management to the health

care system is phenomenal. Some groups have admonished

physicians to exert some financial stewardship. Others have

argued that we cannot withhold treatment if such treatment

is available. Do we need a new set of ethical rules? No one

likes to set priorities or ration care. Discussions within the

medical community alone will not lead to substantial change.

We must have a conversation within the society at large.

Speaker Biography

H Joachim Deeg completed his MD in Wilhelms Universitaet, Germany. Presently

he is working as a Professor of medicine in the University of Washington. He is

also a member of the Fred Hutchinson Cancer Research Center. He is also a visiting

professor at Carl Carus University, Dresden, Germany. His research interests are

Pathophysiology, genetics and epigenetics of MDS (role of transcription factors

in regulation) Inflammatory responses and GVHD (effects of alpha1 anti-trypsin

[AAT]), Separation of GVHD and GVL effects by AAT, Iron and allogeneic responses.

H Joachim Deeg

University of Washington, USA

When do we stop? Modern sequential therapies for hematologic malignancies and

end of life questions